N omega-nitro-L-arginine: a potent inhibitor of the L-arginine-dependent soluble guanylate cyclase activation pathway in LLC-PK1 cells

Can J Physiol Pharmacol. 1990 Jun;68(6):749-51. doi: 10.1139/y90-114.

Abstract

Oxytocin increased cyclic GMP levels in LLC-PK1 porcine kidney epithelial cells through activation of soluble guanylate cyclase. NG-Monomethyl-L-arginine and N omega-nitro-L-arginine inhibited oxytocin (10 microM) induced cyclic GMP accumulation with IC50 values of 2.3 microM and 140 nM, respectively, and the inhibition was prevented with L-arginine. Both inhibitors at 100 microM lowered the basal levels of cyclic GMP, but did not affect those induced by 1 microM sodium nitroprusside and 100 nM atrial natriuretic factor. These data support our hypothesis that an endothelium-derived relaxing factor-like substance is formed as the endogenous activator of soluble guanylate cyclase in an L-arginine-dependent fashion in various cell types. N omega-Nitro-L-arginine is 16 times more potent than NG-monomethyl-L-arginine as a specific inhibitor of this pathway in LLC-PK1 cells.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Arginine / analogs & derivatives*
  • Arginine / pharmacology
  • Cells, Cultured
  • Cyclic GMP / metabolism
  • Dose-Response Relationship, Drug
  • Enzyme Activation / drug effects
  • Guanylate Cyclase / metabolism
  • Nitroarginine
  • Oxytocin / pharmacology

Substances

  • Nitroarginine
  • Oxytocin
  • Arginine
  • Guanylate Cyclase
  • Cyclic GMP